Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jin Law
Goldman Sachs Group, Inc., Research Division

All right. Let’s kick off the next session. Good afternoon, everyone. It is my pleasure to be hosting Olema Oncology and Sean Bohen, CEO of the company. Sean, welcome.

Sean Bohen
President, CEO, Interim Principal Financial Officer & Director

Thank you, Rich.

Jin Law
Goldman Sachs Group, Inc., Research Division

Glad to be hosting you for another year at the GS Conference. Before I — we have a lot to talk about. There’s a lot going on, a lot of stuff coming out later on this year as well. Before we go there, I’m going to turn it to you for opening remarks.

Sean Bohen
President, CEO, Interim Principal Financial Officer & Director

Great. Thank you, Rich. Well, thanks, everyone, for your interest. Just reminding you, Olema is a company focused on changing the treatment paradigm for ER-positive/HER2-negative breast cancer. This is the most common malignancy in women. It’s the second most common cause of cancer death and ER-positive/HER2-negative 70% of it.

And we have 2 clinical stage assets. The first is palazestrant, which is in 2 Phase, three programs ongoing. The first readout, as we will talk about, to be in the fall from OPERA-01 or monotherapy. And then we recently presented data on our KAT6/7 inhibitor at ASCO showing monotherapy activity, both in ER-positive/HER2-negative breast and also castration-resistant prostate cancer. And the combinations are ongoing for breast and to be started for prostate cancer with that molecule.